Fedawed Operative Technique

Stepwise En Bloc Resection of Breast Implant-Associated Anaplastic Large Cell Lymphoma with Oncologic Considerations

Sarah E. Tevis, MD; Kelly K. Hunt, MD, FACS; and Mark W. Clemens, MD, FACS

Abstract

Guidelines published by the National Comprehensive Cancer Network state that standard of care treatment for the majority of patients with breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is surgical resection. This cancer is generally indolent, and if confined to the capsule, curative treatment is usually surgery alone. An en bloc resection involves a total capsulectomy, explantation, complete excision of associated masses, and excision of any involved lymph node(s). Patients with surgical control of disease have favorable long-term overall and event-free survival. Oncologic principles should be applied when resecting BIA-ALCL, and a complete oncologic resection is essential to cure patients of the disease. Incomplete resections, partial capsulectomies, and positive margins are all associated with high rates of disease recurrence and have potential for progression of the disease. Routine sentinel lymph node biopsy is unnecessary and full axillary lymph node dissection is rarely indicated except in cases of proven involvement of multiple nodes. Lymphoma oncology consultation and disease staging by imaging is performed prior to surgery. Importantly, en bloc resection is indicated only for an established diagnosis of BIA-ALCL, and is not recommended for merely suspicious or prophylactic surgeries. The purpose of this article was to demonstrate a stepwise approach to surgical ablation of BIA-ALCL with an emphasis on oncologic considerations critical to disease prognosis.

Surgical management of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has demonstrated improved event-free progression and overall survival in long-term follow-up compared with any other treatment modality. On the basis of this research, the National Comprehensive Cancer Network (NCCN) established consensus standard of care treatment guidelines for the surgical resection of BIA-ALCL. Surgical management of BIA-ALCL has now been recommended by the World Health Organization and the US Food and Drug Administration. BIA-ALCL is generally indolent, and if confined to the capsule, can usually be cured with surgery alone. An en bloc resection involves a total capsulectomy, explantation, complete excision of associated masses, and excision of any involved lymph node(s).

Dr Tevis is an Assistant Professor of Surgery at Department of Surgery, University of Colorado, Aurora, CO. Dr Hunt is the Chair and a Professor at Department of Breast Surgery, University of Texas MD Anderson Cancer Center, Houston, TX. Dr Clemens is an Associate Professor at Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, TX. Dr Clemens is also the Breast Surgery Section Co-editor for Aesthetic Surgery Journal.

Corresponding Author:
Dr Mark W. Clemens, Department of Plastic Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
E-mail: mwclemens@mdanderson.org; Twitter: @clemensmd
In general, plastic surgeons are most familiar with complete capsulectomy performed for capsular contracture associated with implants and they may not be accustomed to oncologic ablation of a lymphoma. Capsulectomy for benign conditions may only be partial, and resection is often performed in a piecemeal fashion. In contrast, oncologic principles should be applied when resecting BIA-ALCL and a complete oncologic resection is essential to curative treatment for the disease. Incomplete resections, partial capsulectomies, and positive margins are all associated with high rates of disease recurrence and, in rare cases, accelerated progression of disease. In this article, we describe a stepwise approach to surgical ablation of BIA-ALCL with an emphasis on oncologic considerations pertinent to a plastic surgery audience.

**Institutional Experience**

A prospective study of all institutional cases from 2013 to 2018 was performed for patients receiving surgical management of BIA-ALCL. Intraoperative techniques and outcomes were reviewed. The study was approved by institutional review board of MD Anderson Cancer Center and all patients submitted written consent. Twenty-six consecutive patients were identified receiving en bloc surgical resection and explantation by the authors. Perioperative complications included one case of pneumothorax (3.8%), treated with closure of the pleural defect over suction without further sequelae. Two disease recurrences (7.8%) were noted at an average of 5 months from surgery. All patients eventually achieved complete remission (100%) and no deaths were reported.

**Patient Selection and Preoperative Evaluation**

The surgical treatment of a patient with pathologically confirmed BIA-ALCL follows a standardized approach set forth by the NCCN. We have previously reviewed the approach to a suspected case and the pathologic workup of a delayed seroma which are outside the scope of this article. In brief, BIA-ALCL most commonly presents with a delayed (>1 year from implantation) periprosthetic fluid collection around a textured implant (Figure 1). Diagnosis of BIA-ALCL is established with: (1) large anaplastic morphology on cytology; (2) a single T-cell clone on flow cytometry; and (3) CD30+ confluent immunohistochemistry. CD30 IHC is a diagnostic test for BIA-ALCL, but by itself is not pathognomonic for the disease as lymphocytes can express trace CD30 in certain inflammatory states. When a patient is found to have BIA-ALCL, a complete evaluation with metastatic workup is indicated prior to surgical intervention. Preoperative evaluation and staging ideally includes a multidisciplinary approach involving a lymphoma oncologist, hematopathologist, plastic surgeon, and a surgical oncologist. A positron emission tomography (PET) computed tomography (CT) scan should be obtained preoperatively to determine the stage of disease and also for surgical planning. Following surgery, PET/CT is unreliable for the detection of disease for several months due to postsurgical inflammation. The preoperative PET/CT scan can serve as an intraoperative surgical roadmap for resection of disease to ensure any associated masses are resected with the specimen. Importantly, an en bloc resection is indicated only for an established diagnosis of BIA-ALCL, and is not recommended for merely suspicious or prophylactic surgeries.

Preoperative markings are made with the patient in a standing position (Figure 2). Chest wall anatomy is highlighted, which includes inframammary folds and breast meridian bilaterally. Note that a large effusion around the breast can dissect tissue planes destroying the inframammary fold or lateral axillary line which may need to be addressed and corrected intraoperatively. NCCN guidelines on BIA-ALCL recommend consideration of contralateral explantation due to known cases of bilateral disease. We recommend en bloc resection of bilateral breast implants and surrounding capsules at the same time. Any previous incisions should be noted and utilized for access to the breast to preserve blood supply. Of note, many patients undergoing a large volume explantation will have significant redundant skin which can be resected in a mastopexy skin excision at the time of explantation (Figure 2B). Some patients may have a mass that involves overlying skin or is particularly close to the skin requiring skin excision. Ideally, skin invasion can also be incorporated into a mastopexy, Wise-pattern, or modified patterns to account for skin loss (Figure 2C). Prophylactic antibiotics are administered intravenously, and sequential compression devices are placed before the induction of anesthesia. Patients with active cancer are at higher risk to develop venous thromboembolism. Patients are positioned supine with the arms abducted on the operating table. Ultrasound evaluation in the operating room can help localize any associated mass or lymphadenopathy (Figure 3). Biopsy confirmed lymph node metastasis should be excised at the time of explantation if feasible.

**Intraoperative Technique**

The procedure for en bloc resection of BIA-ALCL is described in 18 steps and is presented in Table 1. A video that demonstrates the surgical process is available as Supplementary Material. An oncologic en bloc resection consists of explantation, total capsulectomy including the posterior wall along with any associated masses. The excision should be performed en bloc and every effort...
Figure 1. BIA-ALCL patient example. This 43-year-old woman had a past medical history of left breast cancer and bilateral nipple sparing mastectomies and reconstruction with textured (Allergan Corporation, Biocell 410 style, 475 ml) silicone implant reconstruction. Three years following implantation, she developed a left periprosthetic effusion. (A,C,E) Fine needle aspiration demonstrated BIA-ALCL and she underwent a single-stage en bloc resection with explantation, total capsulectomy, and immediate reconstruction with smooth silicone implants. (B,D,F) The patient is shown at 18-month follow-up and remains in complete remission.
should be made to avoid contaminating the wound with tumor. There is no role for total mastectomy, sentinel lymph node biopsy, or routine axillary lymph node dissection in the treatment of BIA-ALCL. Any suspicious or biopsy-proven metastatic lymph nodes warrant excision.

For select patients, subcutaneous tumescence with solution containing lidocaine (0.05% or 0.1%), saline, and epinephrine (1:1,000,000) can help facilitate ablation of the tumor.

**Table 1.** En Bloc Resection of BIA-ALCL with Key Oncologic Principles

<table>
<thead>
<tr>
<th>Surgical management of BIA-ALCL with oncologic technique</th>
</tr>
</thead>
<tbody>
<tr>
<td>• A preoperative PET/CT scan serves as a surgical road map for planning en bloc resection.</td>
</tr>
<tr>
<td>• Mark the patient preoperatively for breast anatomy as well as planned incisions for mastopexy if necessary, reconstruction, and need for skin excision.</td>
</tr>
<tr>
<td>• Intraoperative ultrasound or localization with radioactive or magnetic seeds can localize capsular masses or discrete lymph nodes to facilitate resection.</td>
</tr>
<tr>
<td>• For select patients, tumescence of skin flaps may facilitate ablation.</td>
</tr>
<tr>
<td>• Utilize existing breast incisions.</td>
</tr>
<tr>
<td>• Inframammary approach provides the best exposure for an en bloc resection.</td>
</tr>
<tr>
<td>• Establish dissection plane surrounding the capsule with elevation of overlying skin and parenchymal flaps.</td>
</tr>
<tr>
<td>• Complete capsulectomy should always include the posterior capsule.</td>
</tr>
<tr>
<td>• Tumescence hydrodissection aids in the elevation of the posterior capsule off of the chest wall.</td>
</tr>
<tr>
<td>• Excise suspicious and confirmed lymphadenopathy, avoid sentinel lymph node or full axillary dissection.</td>
</tr>
<tr>
<td>• Ensure meticulous hemostasis.</td>
</tr>
<tr>
<td>• Liberal drain placement.</td>
</tr>
<tr>
<td>• Change instruments for contralateral procedures.</td>
</tr>
<tr>
<td>• Specimen should be oriented for pathology evaluation.</td>
</tr>
<tr>
<td>• Surgical clips should be placed in the tumor bed particularly in an area where a mass is resected.</td>
</tr>
<tr>
<td>• Local anesthetic injection for intercostal blocks with lidocaine/Marcaine or Exparel.</td>
</tr>
<tr>
<td>• Reconstruction with smooth implants or autologous tissue based on stage of disease.</td>
</tr>
<tr>
<td>• Postoperative immobilization in surgical bra.</td>
</tr>
</tbody>
</table>
Tevis et al

while not compromising the blood supply of skin flaps (Figure 4).\textsuperscript{11,12} High-risk patients most amenable to tumescence technique include breast cancer reconstruction patients with previous mastopexy scars or patients with prepectoral subcutaneous reconstructions where the resection of the capsule might overly compromise the skin flap vascularity. Tumescence should be placed just into the subcutaneous plane and not within the breast parenchyma or directly into the capsule. The establishment of tissue planes by tumescence and hydrodissection is oncologically sound and does not disrupt margin status.

Skin incisions are made along previous scars such as along the inframammary fold (Figure 5). Previous transaxillary incisions and periareolar incisions may be too small and too remote to perform an en bloc resection, and therefore adequate access may necessitate an inframammary fold approach. Dissection proceeds


Figure 4. Tumescence of skin flaps. For select patients, tumescence and hydrodissection of skin planes can facilitate ablative surgery. (A) A 58-year-old woman with previous mastopexy. Previous nipple sparing mastectomies, or prepectoral implant placement with thin skin flaps also benefit from hydrodissection (B) which allows for a sharp dissection of tissue and (C) minimal compromise of vascularity. Tumescence should be placed just into the subcutaneous plane and not within the breast parenchyma or directly into the capsule.
through the skin and parenchyma down to, but not into the capsule. A small rim of healthy tissue should be kept around the capsule for evaluation of margins. Tissue flaps are created of skin, subcutaneous fat, and breast parenchyma first superficial and then deep to the capsule and implant. For patients with subpectoral implants, the plane of dissection needs to remain below the level of the muscle to prevent inadvertent resection of the muscle. Prepectoral implants are technically easier to remove off of the posterior chest wall, but may result in particularly thin skin flaps on the anterior surface. We find the PlasmaBlade (Medtronic, Minneapolis, MN) creates less thermal injury and more precise plane of dissection compared with standard electrocautery in these challenging cases.

During surgery, physicians should attempt to adhere to oncologic principles of tumor ablation. This includes changing instruments when moving to a different surgical site such as from one breast to another. An en bloc resection is ideally removed as one specimen with the implant, capsule, and peri-implant fluid collection intact. Care should be made to avoid spillage of the malignant effusion which may lead to spread of the disease along the chest wall. The chest wall is a frequent location of recurrence following partial capsulectomy that leaves the posterior capsule wall. For this reason, the entire capsule needs to be removed with the main specimen (Figure 6A, B). For implants placed in the submuscular position, the capsule may be densely adherent to the ribs and periosteum. Tumescence of the posterior wall can facilitate capsule

Figure 5. Incision and establishment of dissection plane. A 36-year-old woman is shown. En bloc resection is technically easier through an inframammary fold incision (A) and may be more difficult through a periareolar or axillary incision. Incision should utilize previous scars and proceed down to but not entering the capsule. Skin and parenchymal flaps are elevated off of the capsule. (B,C) Care should be taken to stay on the capsule and not resect the pectoralis major muscle with the specimen. BIA-ALCL is not a disease of the breast parenchyma and therefore a mastectomy is not indicated. Counter traction with surgical rakes helps maintain plane of dissection.
Care should be taken to avoid dissection into the intercostal muscles to minimize the risk of pneumothorax, the sole intraoperative complication we have encountered. Small rents in the pleura can be closed over suction through a red rubber tube, whereas a large pneumothorax would require a chest tube placement. If violation of the chest wall and lung pleura is in question during the dissection, a postoperative chest x-ray is recommended to rule out a pneumothorax. At the most distal aspect of resection, a lighted retractor, extended bovie tip, and skin counter traction will facilitate exposure and resection (Figure 7).

En bloc resection of an implant and capsule can lead to significant postoperative pain, particularly in cases involving periosteal stripping along the ribs. Therefore, local anesthetic should be administered intraoperatively to minimize postoperative narcotic requirements. Either a
1% lidocaine/0.5% marcaine mix or Exparel (bupivacaine liposome injectable suspension, Pacira Pharmaceuticals, Parsippany, NJ) injection can be administered with a blunt tip needle for an intercostal nerve block (Figure 8). Typically, intercostal nerves 4-5 are targeted (3 ml per rib), as these nerves provide the majority of sensation to the breast area.

Immediate reconstruction, either autologous or smooth implant, may be performed as clinically indicated based on stage of disease. Note that when performing a smooth implant reconstruction, the pocket must be recreated as resection of the capsule will obliterate the boundaries of the implant. Re-establishment of the lateral fold and inframammary fold can be performed via tissue approximation using absorbable (3-0 polydioxanone [PDS] suture, Ethicon LLC, Somerville, NJ) (Figure 9). Alternatively, if recreation of the anatomic boundaries of the breast pocket is not possible with suture alone, acellular dermal matrix reinforcement of the pocket for soft tissue support may be utilized similar to a standard prosthetic breast reconstruction. The large cavity created by an en bloc resection may be prone to seroma formation particularly in the absence of reconstruction. Therefore, quilting sutures down to the chest wall, fibrin
tissue sealant, liberal use of drains can help minimize this risk. For significant skin redundancy, an immediate mastopexy can be performed based on the size of the implant removed, intrinsic skin laxity, existence of previous scar lines, and amount of excess skin. For resectable disease, stage 1A-2A, we will offer the patient an immediate reconstruction. For invasive disease, questions regarding the completeness of resection, and metastasis, we will delay reconstruction 6 to 12 months to confirm complete remission. At the conclusion of the procedure, patients receive postoperative immobilization in a surgical bra (Figure 10).

Specimens should be oriented for pathologic review to allow for future surgical or radiation therapy planning. Specimen orientation may consist of intraoperative marking of the specimen with ink or marking two margins (superior and lateral) with sutures (Figure 11). Medium-sized surgical clips should be placed in the capsulectomy defect, particularly in any areas directly adjacent to a resected mass, to ensure the location of the excision cavity can be identified on imaging for disease surveillance and the potential for salvage radiation therapy in the setting of recurrence. Consensus on margin adequacy has not been established. Positive margins with cancer cells at the inked edge of the tissue resection have demonstrated high local recurrence rates. At our institution, demonstration of margins with “no ink on tumor” is deemed sufficient. A pathologist may classify the margins as close, lymphoma cells near the edge of the resected tissue, but not right at the edge free of ink (Figure 12).

Figure 8. Local anesthetic. Intercostal nerve blocks decrease postoperative narcotic use and expedite recovery. Local anesthetic with lidocaine/Marcaine or Exparel is injected liberally surrounding the breast cavity and drain sites.

Figure 9. Recreation of anatomic boundaries. An en bloc resection with total capsulectomy can destroy the natural boundaries of the breast such as the lateral and inframammary fold. (A) Demonstrates obliteration of the lateral axillary line of the breast with a cavity well into the patient’s axilla. Immediate smooth implant reconstruction requires recreation of these anatomic boundaries by means of suture approximation of the soft tissue. (B) Demonstrates recreation of the lateral axillary line (yellow box) using an absorbable 3-0 polydioxanone (PDS) suture. Alternatively, acellular dermal matrix may be utilized for soft tissue support to replace the resected scar capsule.
Postoperative Considerations

Following en bloc resection, most patients will be discharged on the same day or with 23-hr observation in an outpatient setting. For smooth implant reconstruction, a supportive bra is maintained 4 to 6 weeks to prevent displacement and device malposition. Patients treated with complete resection are followed with history and physical examination every 3 to 6 months for 2 years postoperatively. Drain tube removal generally occurs at 2 to 3 weeks. Patients with residual disease or who underwent incomplete resection require evaluation by a multidisciplinary team to discuss adjuvant chemotherapy and/or radiation therapy.
DISCUSSION

BIA-ALCL is typically indolent in nature and prognosis following complete resection is very good. An evaluation of 74 patients with breast implant ALCL who were treated with complete oncologic resection demonstrated event rates (local and distant) of 0% for stage T1 or T2 disease and 14.3% for T4 disease ($P < 0.001$). BIA-ALCL has been shown to metastasize to regional nodal basins, bone, small bowel, liver, and skin in rare cases, particularly following incomplete resections of disease. To date, 16 patient deaths have been reported in association with BIA-ALCL which emphasizes that BIA-ALCL is a lymphoma, a malignancy, and the ability to invade surrounding tissue demonstrates the need for prompt diagnosis and adequate treatment. Patients should ideally be evaluated by oncology preoperatively so that the patient may be followed up for disease surveillance. Clinical examination is recommended at intervals of 3 to 6 months with surveillance PET/CT scan at 6-month intervals for at least 2 years.

CONCLUSION

Complete en bloc surgical excision is essential for curative treatment of BIA-ALCL. A complete resection should include removal of the entire capsule as well as any associated masses and any suspicious lymph nodes. Oncologic principles such as specimen orientation and placing clips in the tumor cavity should be employed during oncologic ablation. An en bloc resection is indicated only for an established diagnosis of BIA-ALCL, and is not recommended for merely suspicious or prophylactic surgeries. When treated appropriately and in a timely fashion, BIA-ALCL has an excellent prognosis.

Supplementary Material

This article contains supplementary material located online at http://www.asjopenforum.com.

Disclosures

The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

The authors received no financial support for the research, authorship, and publication of this article.

REFERENCES

15. Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship between margin width and recurrence of

